CC
AARD

Centiva Capital’s Aardvark Therapeutics AARD Stock Holding History

Centiva Capital’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93.4K Sell
24,782
-72,738
-75% -$754K ﹤0.01% 1397
2025
Q4 		$1.28M Buy
+97,520
New +$1.22M 0.01% 514

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Centiva Capital's AARD Position: Q1 2026 in Review

Centiva Capital reduced its Aardvark Therapeutics (AARD) stake by 75% in Q1 2026, selling an estimated $754K and leaving 24,782 shares worth $93.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1397.

Centiva Capital first reported a position in AARD in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.28M in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Centiva Capital held 24,782 shares of Aardvark Therapeutics worth $93.4K as of Q1 2026.
  • Centiva Capital sold 72,738 Aardvark Therapeutics shares in Q1 2026, an estimated $754K.
  • Aardvark Therapeutics made up ﹤0.01% of Centiva Capital's portfolio in Q1 2026, its #1397 holding.
  • Centiva Capital first reported a position in Aardvark Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Centiva Capital's Aardvark Therapeutics position peaked at $1.28M in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.